Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections

Overview

Journal Infect Dis Ther

Specialty Infectious Diseases

Date 2017 Apr 8

PMID 28386776

Citations 29

Authors

Cassie L Stewart

Michelle S Turner

Jeremy J Frens

Cynthia B Snider

Jordan R Smith

Affiliations

Soon will be listed here.

Abstract

Introduction: Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfortunately, data for using oritavancin in these populations are limited.

Methods: We report ten cases of oritavancin use for invasive Gram-positive infections in our health system, and provide a review of the currently available literature regarding oritavancin therapy for invasive infections.

Results: Among the ten patients who received oritavancin, the most common infection was methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia (n = 5, 50%). Other indications for oritavancin use included methicillin-resistant S. aureus (MRSA) bursitis (n = 1, 10%), group B streptococcal bacteremia with native tricuspid valve infective endocarditis (n = 1, 10%), coagulase-negative staphylococcal bacteremia (n = 1, 10%), MSSA deep tissue infection (n = 1, 10%), and enterococcal bacteremia (n = 1, 10%). Oritavancin was well tolerated, and 7/10 (70%) patients were successfully treated.

Conclusion: Oritavancin is a potential option for patients with invasive Gram-positive infections. Further study is warranted.

Citing Articles

Long-term oritavancin therapy for shoulder prosthetic joint infection: A case guided by therapeutic drug monitoring (TDM).

Buonomo A, Cattaneo L, Viceconte G, Calabria F, Di Troia G, Di Fusco A IDCases. 2024; 38:e02105.

PMID: 39582750 PMC: 11584596. DOI: 10.1016/j.idcr.2024.e02105.

In silico molecular targets, docking, dynamics simulation and physiologically based pharmacokinetics modeling of oritavancin.

Fatoki T, Balogun T, Ojewuyi A, Omole A, Olukayode O, Adewumi A BMC Pharmacol Toxicol. 2024; 25(1):79.

PMID: 39439008 PMC: 11520145. DOI: 10.1186/s40360-024-00804-z.

New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides.

Siciliano V, Sangiorgi F, Del Vecchio P, Vahedi L, Gross M, Saviano A Pathogens. 2024; 13(3).

PMID: 38535533 PMC: 10975219. DOI: 10.3390/pathogens13030189.

Oritavancin as sequential therapy for Gram-positive bloodstream infections.

Texidor W, Miller M, Molina K, Krsak M, Calvert B, Hart C BMC Infect Dis. 2024; 24(1):127.

PMID: 38267844 PMC: 10807122. DOI: 10.1186/s12879-023-08725-8.

New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.

Oliva A, Cogliati Dezza F, Cancelli F, Curtolo A, Falletta A, Volpicelli L J Clin Med. 2023; 12(24).

PMID: 38137762 PMC: 10743892. DOI: 10.3390/jcm12247693.

References

Johnson J, Feeney E, Kubiak D, Corey G . Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis. Open Forum Infect Dis. 2015; 2(4):ofv156. PMC: 4677157. DOI: 10.1093/ofid/ofv156. View

Morrissey I, Seifert H, Canton R, Nordmann P, Stefani S, MacGowan A . Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother. 2012; 68(1):164-7. DOI: 10.1093/jac/dks344. View

Corey G, Kabler H, Mehra P, Gupta S, Overcash J, Porwal A . Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014; 370(23):2180-90. DOI: 10.1056/NEJMoa1310422. View

Duncan L, Sader H, Flamm R, Jones R, Mendes R . Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013-2014). Diagn Microbiol Infect Dis. 2016; 86(3):303-306. DOI: 10.1016/j.diagmicrobio.2016.07.025. View

Rybak M, Lomaestro B, Rotschafer J, Moellering Jr R, Craig W, Billeter M . Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2008; 66(1):82-98. DOI: 10.2146/ajhp080434. View

Menichetti F . Current and emerging serious Gram-positive infections. Clin Microbiol Infect. 2005; 11 Suppl 3:22-8. DOI: 10.1111/j.1469-0691.2005.01138.x. View

Corey G, Good S, Jiang H, Moeck G, Wikler M, Green S . Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2014; 60(2):254-62. DOI: 10.1093/cid/ciu778. View

Dunbar L, Milata J, McClure T, Wasilewski M . Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother. 2011; 55(7):3476-84. PMC: 3122413. DOI: 10.1128/AAC.00029-11. View

Liu C, Bayer A, Cosgrove S, Daum R, Fridkin S, Gorwitz R . Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52(3):e18-55. DOI: 10.1093/cid/ciq146. View

10.

Smith J, Yim J, Raut A, Rybak M . Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci. Antimicrob Agents Chemother. 2016; 60(4):2352-8. PMC: 4808215. DOI: 10.1128/AAC.03006-15. View

11.

Mendes R, Sader H, Flamm R, Farrell D, Jones R . Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program. Antimicrob Agents Chemother. 2014; 58(5):2921-4. PMC: 3993239. DOI: 10.1128/AAC.02482-13. View

12.

Cosgrove S, Sakoulas G, Perencevich E, Schwaber M, Karchmer A, Carmeli Y . Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2002; 36(1):53-9. DOI: 10.1086/345476. View

13.

Rubino C, Bhavnani S, Moeck G, Bellibas S, Ambrose P . Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother. 2015; 59(6):3365-72. PMC: 4432154. DOI: 10.1128/AAC.00176-15. View

14.

Mendes R, Woosley L, Farrell D, Sader H, Jones R . Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010. Antimicrob Agents Chemother. 2011; 56(3):1639-42. PMC: 3294904. DOI: 10.1128/AAC.06067-11. View

15.

Tice A, Rehm S, Dalovisio J, Bradley J, Martinelli L, Graham D . Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis. 2004; 38(12):1651-72. DOI: 10.1086/420939. View

16.

Van Hal S, Jensen S, Vaska V, Espedido B, Paterson D, Gosbell I . Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012; 25(2):362-86. PMC: 3346297. DOI: 10.1128/CMR.05022-11. View

17.

Sievert D, Ricks P, Edwards J, Schneider A, Patel J, Srinivasan A . Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2012; 34(1):1-14. DOI: 10.1086/668770. View

18.

Rubino C, Van Wart S, Bhavnani S, Ambrose P, McCollam J, Forrest A . Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009; 53(10):4422-8. PMC: 2764228. DOI: 10.1128/AAC.00231-09. View

19.

Mellor J, Kingdom J, Cafferkey M, Keane C . Vancomycin ototoxicity in patients with normal renal function. Br J Audiol. 1984; 18(3):179-80. DOI: 10.3109/03005368409078946. View